Advances of Photothermal Agents with Fluorescence Imaging/Enhancement Ability in the Field of Photothermal Therapy and Diagnosis
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.3c01073 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Siyi Yuan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hubei Key Laboratory of Plasma Chemistry and Advanced Materials, School of Material Science and Engineering, Wuhan Institute of Technology, Wuhan 430…. Hauptthemen laut MEDLINE: Nanoparticles, Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 91 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Innovation and Entrepreneurship Training Program Funded by Wuhan Institute of Technology.
Abstract (Originalsprache)
Photothermal therapy (PTT) is an effective cancer treatment method. Due to its easy focusing and tunability of the irradiation light, direct and accurate local treatment can be performed in a noninvasive manner by PTT. This treatment strategy requires the use of photothermal agents to convert light energy into heat energy, thereby achieving local heating and triggering biochemical processes to kill tumor cells. As a key factor in PTT, the photothermal conversion ability of photothermal agents directly determines the efficacy of PTT. In addition, photothermal agents generally have photothermal imaging (PTI) and photoacoustic imaging (PAI) functions, which can not only guide the optimization of irradiation conditions but also achieve the integration of disease diagnosis. If the photothermal agents have function of fluorescence imaging (FLI) or fluorescence enhancement, they can not only further improve the accuracy in disease diagnosis but also accurately determine the tumor location through multimodal imaging for corresponding treatment. In this paper, we summarize recent advances in photothermal agents with FLI or fluorescence enhancement functions for PTT and tumor diagnosis. According to the different recognition sites, the application of specific targeting photothermal agents is introduced. Finally, limitations and challenges of photothermal agents with fluorescence imaging/enhancement in the field of PTT and tumor diagnosis are prospected.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hubei Key Laboratory of Plasma Chemistry and Advanced Materials, School of Material Science and Engineering, Wuhan Institute of Technology, Wuhan 430205, China.
- Key Laboratory of Green Chemical Process Ministry of Education, Wuhan Institute of Technology, Wuhan 430205, China.
- College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China.
Förderung
- National Natural Science Foundation of China
- Innovation and Entrepreneurship Training Program Funded by Wuhan Institute of Technology
Zitieren
APA
Yuan, S., Zhou, J., Wang, J., Ma, X., Liu, F., Chen, S., Fan, J. X., & Yan, G. P. (2024). Advances of Photothermal Agents with Fluorescence Imaging/Enhancement Ability in the Field of Photothermal Therapy and Diagnosis. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c01073
Vancouver
Yuan S, Zhou J, Wang J, Ma X, Liu F, Chen S, et al. Advances of Photothermal Agents with Fluorescence Imaging/Enhancement Ability in the Field of Photothermal Therapy and Diagnosis. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.3c01073
BibTeX
@article{Yuan2024,
author = {Yuan, Siyi and Zhou, Jun and Wang, Juntong and Ma, XiaoYu and Liu, Fan and Chen, Si and Fan, Jin-Xuan and Yan, Guo-Ping},
title = {Advances of Photothermal Agents with Fluorescence Imaging/Enhancement Ability in the Field of Photothermal Therapy and Diagnosis},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.3c01073}
}
EUVIMED